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CME Objective for This Article:
At the completion of this article, the learner should be able to discuss the:
• The poor clinical outcomes in critically ill patients presenting with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock and resuscitated cardiac arrest.
• The concept that the degree of myocardial ischemia impacts patient outcomes and may vary according to the number of significant coronary stenoses.
• That percutaneous coronary intervention of the only infarct related artery (IRA) is the treatment of choice for non-shock STEMI patients.
• And finally, that in patients with persistent cardiogenic shock following IRA-PCI, intervention to other significant coronary lesions supplying a large non-IRA territory may enhance survival.
Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction, Resuscitated Cardiac Arrest, and Cardiogenic Shock
The Role of Primary Multivessel Revascularization
Objectives This study sought to assess the impact of multivessel (MV) primary percutaneous coronary intervention (PCI) on clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) presenting with cardiogenic shock (CS) and resuscitated cardiac arrest (CA).
Background The safety and efficacy of MV primary PCI in patients with STEMI and refractory CS is unknown.
Methods We conducted a multicenter prospective observational study of consecutive STEMI patients presenting to 5 French centers. Patients were classified as having single-vessel (SVD) or multivessel (MVD) coronary disease, and underwent culprit-only or MV primary PCI. Baseline characteristics and 6-month survival were compared.
Results Among 11,530 STEMI patients, 266 had resuscitated CA and CS. Patients with SVD (36.5%) had increased 6-month survival compared to those with MVD (29.6% vs. 42.3%, p ϭ 0.032). Baseline characteristics were similar in those with MVD undergoing culprit-only (60.9%) or MV (39.1%) primary PCI. However, 6-month survival was significantly greater in patients who underwent MV PCI (43.9% vs. 20.4%, p ϭ 0.0017). This survival advantage was mediated by a reduction in the composite of recurrent CA and death due to shock (p ϭ 0.024) in MV PCI patients. In those with MVD, culprit artery PCI success (hazard ratio Increased availability of primary percutaneous coronary intervention (PCI) has reduced the incidence of cardiogenic shock (CS) in patients with ST-segment elevation myocardial infarction (STEMI) (1) . In STEMI patients with established CS, prompt primary PCI of the infarct-related artery (IRA) improves survival (2); however, mortality remains unacceptably high (ϳ50%), and is even worse in patients who have been resuscitated from cardiac arrest (3).
See page 126
The majority of patients with STEMI and CS have multivessel coronary artery disease (MVD). Multivessel disease is more likely to induce widespread myocardial ischemia and progressive left ventricular dysfunction, and has been associated with increased mortality (4). Not surprisingly, multivessel (MV) revascularization during primary PCI has been proposed as a strategy with the potential to improve outcomes in patients with MVD and persistent CS. Current societal guidelines concur (5,6); however, there is little evidence to support this strategy (7), which could conversely worsen outcomes by increasing the risk of non-IRA distal embolization, stent thrombosis, and contrast nephropathy (8) .
To investigate the safety and efficacy of MV primary PCI, we conducted a multicenter study of patients with STEMI, CS, and resuscitated cardiac arrest, and compared clinical outcomes in patients treated with either culprit-only or MV primary PCI.
Methods
Patient population. Between 1998 and 2010, we prospectively collected data from consecutive unselected patients presenting with STEMI in 5 French centers. The study population was derived from 11,530 patients admitted with STEMI, among whom 4.3% (n ϭ 496) had resuscitated cardiac arrest, 9.8% (n ϭ 1,130) had CS, and 2.4% (n ϭ 272) presented with both resuscitated cardiac arrest and CS (Fig. 1) .
Patients were selected for the current study if they had been resuscitated from cardiac arrest, met the criteria for STEMI and CS, and had a culprit lesion on coronary angiography, Ͻ24 h after the onset of ischemia. This patient population was specifically chosen as it represents the highest-risk patient group encountered by interventional cardiologists, and in light of the cardiac arrest, are the most likely to have ongoing global myocardial ischemia. Patients were excluded if further resuscitation was deemed futile on arrival at the catheterization laboratory, an alternative cause of shock was suspected, or if a mechanical complication of myocardial infarction (MI) was determined before PCI. The study complied with the Declaration of Helsinki. Pre-hospital management. Pre-hospital medical care was performed by the emergency medical service (EMS) (Service d'Aide Médicale Urgence) as described previously (3) . External defibrillation; administration of inotropic, paralytic, and antiarrhythmic drugs; and mechanical ventilation were routinely performed according to approved guidelines. According to the Utstein template (9), resuscitated patients with obvious extracardiac causes were investigated and treated according to standard critical care procedures. In the absence of an obvious extracardiac cause, survivors were transferred directly to cardiac catheterization laboratories under continuous electrocardiogram (ECG) monitoring. At least 1 pre-hospital 12-lead ECG was recorded in all patients. In-hospital evaluation and treatment. All patients underwent a rapid clinical evaluation and immediate coronary angiography with a view to performing primary PCI. Hemodynamic status was cautiously evaluated on admission and during angiography. Our default strategy was to perform primary PCI in these high-risk, hemodynamically unstable patients unless, a mechanical complication, deemed coronary artery bypass graft (CABG) surgery to be more appropriate. All decisions regarding the PCI, including the number of vessels treated, were solely at the discretion of the treating physician. All patients were treated with intravenous heparin (1 mg/kg body weight) and aspirin (250 to 500 mg) before PCI. Further doses of heparin were given as required to maintain an activated clotting time of 300 to 350 s. A loading dose of 300 to 600 mg of clopidogrel was given before PCI, or immediately after the procedure through a nasogastric tube in unconscious patients.
Intensive medical care was provided in dedicated cardiac intensive care units for all patients following PCI. Mild therapeutic hypothermia, renal replacement therapy, and left ventricular assist devices were used where appropriate. Data collection and follow-up. Data were prospectively collected using the Utstein-style guidelines for cardiac arrest (9) . Adverse cardiac events, including recurrent cardiac arrest, reinfarction, and early urgent revascularization were recorded. Cerebral Performance Categories Scale scores of outcome, graded 1 to 4, were calculated at hospital discharge for all survivors as follows: 1 ϭ conscious and alert with good cerebral performance; 2 ϭ conscious with moderate cerebral disability; 3 ϭ conscious with severe disability and dependent on others for activities of daily living; and 4 ϭ comatose or persistent vegetative state (10) . Clinical follow-up was performed by hospital visit or patient/nextof-kin telephone interview at 6 months. Study definitions. Cardiogenic shock was defined on admission according to the clinical criteria described in the SHOCK (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock) trial (2): systolic blood pressure Ͻ90 mm Hg for Ͼ30 min or the requirement for supportive measures to maintain blood pressure Ն90 mm Hg, and evidence of end-organ hypoperfusion (cool extremities, urine output Ͻ30 ml/h, and a heart rate Ն60 beats/min). The diagnosis of CS was verified by the assessment of the original EMS patient encounter forms by an independent physician. Acute MI was defined as ECG evidence of Ͼ2-mm STsegment elevation in Ն2 contiguous leads or a left bundle branch block or a posterior infarction with anterior ST-segment depression, and at least 1 culprit lesion on angiography. Cardiac arrest was defined as the cessation of cardiac mechanical activity as confirmed by the absence of signs of circulation (9) . A cardiac arrest in medical care indicated an arrest occurring either in-hospital or in the presence of the EMS.
Multivessel coronary disease was defined as the presence of an additional significant stenosis (Ն70%) in a major (Ն2.5-mm diameter) non-IRA, or as a distal left main lesion with significant stenosis of the ostia of both the daughter arteries. Immediate PCI of a stenosis Ն70% in a non-IRA during the index procedure, not including branches of the IRA, and PCI of both branches of the distal left main defined MV primary PCI. Intervention to a non-IRA remote from the index procedure was not consid- 
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Revascularization in STEMI With Shock and Arrest ered as MV primary PCI. Angiographic success in the IRA was defined as residual stenosis Յ30% and a final Thrombolysis in Myocardial Infarction (TIMI) flow grade Ͼ2.
Reinfarction was defined as follows: 1) if the peak creatinine kinase (CK)-MB fraction (or CK) from the index infarction had not yet been reached: recurrent ischemic symptoms Ն20 min in duration or new ECG changes consistent with MI, and the peak CK-MB (or CK in the absence of CK-MB) level measured within 24 h after the event was elevated by at least 50% above the previous level; 2) if the elevated CK-MB (or CK) level from the index infarction was falling or had returned to normal: recurrent ischemic symptoms lasting Ն20 min in duration, or new ECG changes consistent with MI, and a new elevation of CK-MB (or CK) greater than the upper limit of normal (ULN) if the patient was being treated medically, or CK-MB/CK Ͼ3ϫ ULN within 24 h post-PCI if the CK-MB (or CK) level has returned to ϽULN, or a rise by Ͼ50% above the previous nadir level (and Ͼ3ϫ ULN if post-PCI) if the CK-MB (or CK) level has not returned to ϽULN (11). The cause of death was defined as follows: CS, death due to persistent hypotension, refractory heart failure, or multiorgan failure; anoxia death due to a persistent vegetative state; arrhythmia death due to recurrent intractable cardiac arrest; sepsis death, death due to overwhelming systemic infection. All clinical events, including the cause of death, were adjudicated by 2 independent physicians blinded to the patient's initial treatment strategy.
Outcome variables. The primary outcome measure of the study was 6-month survival. Secondary endpoints included death due to CS, recurrent cardiac arrest, and a composite of these endpoints.
Statistical analysis. Continuous variables are presented as mean Ϯ SD or median and (interquartile range), and were compared with the Student t test or Mann-Whitney test, according to distribution. Categorical variables are presented as numbers and percentages, and were compared using the chi-square test or Fisher exact test. Survival at 6 months was calculated and analyzed by the Kaplan-Meier method, and differences between Kaplan-Meier curves were analyzed with the log-rank test. A multiple Cox regression analysis was performed to assess predictors of 6-month survival, including all baseline and treatment characteristics associated with 6-month survival in the univariate analysis (p Ͻ 0.10), and had availability in the database Ͼ85%. The effect of MV primary PCI on 6-month survival in patients with MVD was assessed by a separate multiple Cox regression analysis. A 2-tailed p value of Ͻ0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 17.0 (SPSS, Chicago, Illinois).
Results
Baseline demographic and clinical characteristics. A total of 272 STEMI patients met the criteria for resuscitated cardiac arrest and CS. Six patients with mechanical complications were referred for urgent CABG and were excluded from the analysis. The baseline demographics of the remaining 266 patients are presented in Table 1 Schematic representation of the study population. PCI ϭ percutaneous coronary intervention.
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Mylotte et al. (Table 2) . Angiographic and treatment data. The culprit lesion was most commonly located in the left anterior descending coronary (51.9%), and was in the left main in 9.8% of cases (Table 3) . The majority of patients had MVD (63.5%), and 18.8% had a non-IRA chronic total occlusion. Despite the high prevalence of MVD, most patients underwent culpritonly PCI (75.2%) ( CABG ϭ coronary artery bypass grafting; CAD ϭ coronary artery disease; MI ϭ myocardial infarction; MV ϭ multivessel; MVD ϭ multivessel disease; PCI ϭ percutaneous coronary revascularization; ROSC ϭ resumption of spontaneous circulation; SVD ϭ single vessel disease.
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Mylotte et al. Fig. 2B ). This survival advantage was mediated by a significant reduction in the composite endpoint of recurrent cardiac arrest/shock death in the MV primary PCI group (50.0% vs. 68.0%, p ϭ 0.024).
Association of baseline characteristics and treatment with
6-month mortality. Univariable analysis of the entire population revealed that 4 characteristics were associated with 6-month mortality (p Ͻ 0.10): 1) an asystolic cardiac arrest; 2) a right coronary IRA; 3) MV primary PCI; and 4) angiographic success in the IRA (Table 6) LBBB ϭ left bundle branch block; GFR ϭ glomerular infiltration rate; other abbreviations as in Table 1 .
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Discussion
In the present study, we found that STEMI patients with CS, resuscitated cardiac arrest, and MVD, had significantly greater survival following MV primary PCI compared with culprit-only primary PCI. The results of this study suggest that more complete upfront revascularization has the potential to improve outcomes in these critically ill patients. The SHOCK trial confirmed that prompt revascularization improves survival in CS (2); however, the optimal revascularization strategy for shock patients with MVD is not clear. This is of particular relevance because MVD occurs in up to 87% of patients with CS (12) and is associated with increased mortality (4, 13) . Certainly, there is a rationale for more complete revascularization in MVD patients with CS refractory to IRA intervention. Mortality in CS is directly related to the degree of myocardial ischemia and the extent of acute left ventricular dysfunction (2) . Therefore, treatment of significant non-IRA stenoses which supply a large area of myocardium has the potential to improve left ventricular function, by enhancing perfusion of the periinfarct area and minimizing non-IRA ischemia. Pathological studies have also demonstrated that those who die from MI frequently have evidence of multiple separate thrombi in separate territories, despite a clear culprit lesion (14) .
In the setting of nonshock STEMI, MV primary PCI is inappropriate (5, 6) , as several trials have illustrated the deleterious effects of this approach (15) (16) (17) (18) . By contrast, the safety and efficacy of MV primary PCI in STEMI with CS is unclear. Current societal guidelines support MV primary PCI as a possible treatment strategy for refractory CS (5,6), though supporting evidence is insufficient. Analysis of the PCI cohort in the SHOCK trial (n ϭ 82) suggested that MV primary PCI was associated with increased 1-year mortality (19) . However, PCI in the SHOCK trial does not reflect contemporary practice: 34% received a stent; and only 71% had angiographic success (final TIMI flow grade Ͼ2). In the current study, the IRA was stented in 95.1%, and angiographic success was achieved in 80.5%.
Previous retrospective analyses of large PCI databases have investigated the effect of multivessel PCI on clinical outcomes in patients with STEMI and CS, with somewhat conflicting results (20, 21) . Cavander et al. (20) found that multivessel PCI was associated with increased mortality at 1 year, whereas an analysis by Bauer et al. (21) did not find multivessel PCI to have any impact on in-hospital mortality. Values are mean Ϯ SD or n (%).
CTO ϭ chronic total occlusion; TIMI ϭ Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1 .
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By contrast, the current study observed a considerable survival advantage associated with MV primary PCI. These disparate results must be viewed within the context of the patient population enrolled and the limitations of observational study design. The current study included the highestrisk cohort of patients studied to date, with both STEMI and resuscitated cardiac arrest, in an attempt to ensure the presence of shock and global myocardial ischemia. Previous studies have included lower-risk patient populations: intraaortic balloon pump use (11.1% to 33.3%) and in-hospital mortality (36.5% to 48.8%). The inclusion of nonshock patients in these analyses may have mitigated any benefit associated with MV primary PCI. Furthermore, the prospective design of the current study afforded the availability of individual patient data, thus ensuring adherence to the patient selection criteria and the exclusion of patients with late presentations after symptom onset or those who underwent staged MV PCI. The survival advantage observed in patients undergoing MV primary PCI was mediated by a reduction in events directly related to CS: recurrent cardiac arrest and death due to shock (68% vs. 50%, p ϭ 0.024). A reduction in the overall myocardial ischemic burden in these critically ill patients is a possible explanation for these results. The equivalent 6-month survival in patients with MVD undergoing MV primary PCI (43.9%) and those with SVD (42.3%) are consistent with this hypothesis. Moreover, these data suggest that although complete revascularization results in a survival benefit in these unstable patients, there is a limit to what can be achieved with revascularization. However, among survivors, favorable neurological outcomes were observed (89.5%), and thus, an initial aggressive treatment strategy is probably warranted.
Previous publications have identified early revascularization, left ventricular function, coronary stenting, patient age, and successful revascularization (TIMI flow grade Ͼ2) to be of critical importance when treating patients with CS (2, 22, 23) . Angiographic success in the IRA was also an independent predictor of survival (HR: 0.54 95% CI: 0.37 to 0.78, p ϭ 0.001) in the current study, as was MV primary PCI in those with MVD (HR: 0.57; 95% CI: 0.38 to 0.84, p ϭ 0.005).
Urgent CABG is another possible strategy for treating patients with STEMI and CS (24) . However, clinical practice reflects physician preference for PCI, as a more rapid, less invasive revascularization strategy: the rate of primary PCI for CS has increased (27.4% to 54.4%), whereas the rate of CABG remains stable (2.1% to 3.2%) (1) .
Ultimately, the revascularization strategy for each patient with STEMI and CS should be individualized. In patients with MVD, the hemodynamic status should be reassessed following PCI of the IRA. If CS persists, MV primary PCI should be considered, depending on the complexity of the nonculprit lesions and their capacity to induce myocardial ischemia. We provide preliminary evidence that this strategy may improve clinical outcomes, supporting what is intuitively proposed by practice guidelines and practiced by physicians worldwide, and underscoring the need for adequately powered randomized trials to define the role of more complete revascularization in these critically ill patients. Values are mean Ϯ SD or n (%).
GP ϭ glycoprotein; IRA ϭ infarct-related artery; other abbreviations as in Tables 1 and 3 . Mylotte et al.
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Study limitations. The present study is a nonrandomized, observational registry, and is thus limited by patient selection bias. The decision to perform primary culpritonly or MV primary PCI was based on operator preference. Although the baseline clinical and angiographic characteristics were well matched between patients undergoing culprit-only or MV primary PCI, the culpritonly group tended to be older; have longer no-flow, arrest to defibrillation, and ROSC intervals; and were more likely to have TIMI 0 flow grade on presentation. These factors could have resulted in inferior outcomes in the culprit-only cohort. Unrecognized confounding variables also have the potential to influence nonrandomized results. At the time of study conception, it was not recognized that intervals, such as the door to balloon and first medical contact to balloon were associated with improved survival in STEMI. These intervals would have provided useful additional information. Similarly, serum lactate levels and the resuscitation intervals were not tested in the multivariate analysis because the data were not available in Ͼ85% of cases. However, we have previously identified these factors as independent predictors of survival in STEMI patients with resuscitated cardiac arrest (3). Despite current recommendations, the use of therapeutic hypothermia worldwide remains poor (22) . In the current study, therapeutic hypothermia was used in only 22.2% of cases, and more extensive implementation may have improved outcomes (25) . CPC ϭ Cerebral Performance Categories; other abbreviations as in Table 1 .
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